Novo Nordisk is shipping more introductory doses of its blockbuster weight-loss drug Wegovy in the US as it grapples with supply constraints and competition from Eli Lilly & Co. CEO Lars Fruergaard Jorgensen says the company will continue to ramp up supply of its popular weight-loss drug "gradually." He spoke with Bloomberg's Katie Greifeld and Romaine Bostick.

Former NY Governor Andrew Cuomo Talks Crypto, Midterms
16:41

JPMorgan's Dimon, Gov. Whitmer and Ford's Farley Talk the Michigan Lift
15:53

Gary Gensler Talks AI Competition with China
13:28